- Home
- DSL vs CVAC Comparison
DSL vs CVAC Comparison
Compare DSL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSL | CVAC |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DSL | CVAC |
|---|---|---|
| Price | $11.32 | $5.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 661.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-24-2025 |
| Dividend Yield | ★ 11.59% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | N/A | ★ 0.94 |
| Revenue | N/A | ★ $83,000,117.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.40 |
| P/E Ratio | ★ N/A | $5.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.58 | $2.48 |
| 52 Week High | $13.00 | $5.72 |
Technical Indicators
Market Signals| Indicator | DSL | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 41.42 |
| Support Level | $11.28 | $4.95 |
| Resistance Level | $11.42 | $5.55 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 40.02 | 28.33 |
Price Performance
Historical ComparisonAbout DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.